Twist Bioscience Corp

Twist Bioscience Corp is a U.S.-based synthetic biology company that manufactures synthetic DNA and related life-science products using a proprietary silicon-based DNA writing platform. Its offerings support customers in healthcare, academic research, food and agriculture, and industrial applications, with sales made through direct channels, distributors, and an e-commerce platform.

−29,6 %

50,7 %

−20,6 %

+20,3 %

3.64

3.33

— Twist Bioscience Corp
%
NGS tools / NGS applications55% Products and workflows used in next-generation sequencing and DNA reading applications.
Synthetic genes30% Custom DNA sequences manufactured for research, discovery, and engineering biology.
Oligo pools6% Massively parallel oligonucleotide libraries used in screening and research workflows.
Antibody discovery6% Biopharma services for antibody discovery, optimization, and development.
DNA libraries3% Prepared DNA libraries used in sequencing, screening, and research applications.

Twist sells to a broad base of more than 3,800 customers across healthcare, academic research, industrial, and...

  • Healthcare / biopharmaprimary

    Buys synthetic DNA, antibody discovery, and protein-related services for therapeutic research and development.

  • Academic researchprimary

    Buys custom DNA, libraries, and sequencing tools for discovery, validation, and education.

  • Industrial chemicals/materialssecondary

    Buys DNA-based products to support engineering of specialty chemicals and materials.

  • Food and agriculturesecondary

    Buys synthetic biology tools for crop improvement and agricultural R&D.

  • NGS usersprimary

    Buys NGS tools and applications for sequencing workflows and sample preparation.

Twist sells globally, with revenues reported across the Americas, EMEA, and APAC. The Americas are the largest region,...

  • •Americas accounted for 60% of revenue in fiscal 2025
  • •EMEA accounted for 33% of revenue in fiscal 2025
  • •APAC accounted for 7% of revenue in fiscal 2025
  • •Commercial consultants support sales in Europe and Asia
  • •Revenue is based on customer shipping addresses

Twist’s strategy centers on scaling its silicon-based DNA synthesis platform across more product lines and end markets...

01
Expand platform breadthmedium-term

A wider product set increases customer wallet share and cross-selling across research workflows.

02
Scale digital and direct sales channelsshort-term

The customer base is broad and fragmented, so efficient ordering and support improve reach and retention.

03
Increase biopharma and healthcare penetrationmedium-term

These end markets can use multiple Twist products and services across discovery workflows.

Twist depends heavily on proprietary DNA synthesis technology, so intellectual property protection, biosecurity...

high

Intellectual property protection

The business depends on proprietary synthesis methods and software that competitors could attempt to copy or design around.

Scope
Core platform and manufacturing process
Materiality
high
high

Biosecurity and regulatory compliance

DNA synthesis is subject to biosafety and biosecurity rules that can limit what sequences can be produced and how orders are screened.

Scope
Manufacturing and order screening
Materiality
high
medium

Customer concentration and retention

Revenue can be affected if a limited number of large customers reduce orders or switch suppliers.

Scope
Synthetic DNA and NGS customer base
Materiality
medium
medium

Competitive pressure

The company operates in a technically demanding market where rivals can compete on price, speed, and service.

Scope
Synthetic biology and sequencing workflows
Materiality
high
medium

Reputational risk from product use

Customers may use DNA products in ways that attract scrutiny or damage trust in the platform.

Scope
Global sales and distribution
Materiality
medium
Revenue recognition
Reported revenue mix and timing
Long-lived asset impairment
Operating results and asset carrying values
Gain on sale of business
Net income and comparability
Estimates and judgments
Balance sheet and earnings volatility

HARVARD BIOSCIENCE INC

HBIO · Laboratory Analytical Instruments

Solid Biosciences Inc.

SLDB · Biological Products, (No Diagnostic Substances)

Xenetic Biosciences, Inc.

XBIO · Pharmaceutical Preparations

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

BioScience Health Innovations, Inc.

BHIC · Services-Computer Processing & Data Preparation

CRISPR Therapeutics AG

CRSP · Biological Products, (No Diagnostic Substances)

: 29/04/2026